WO2023133260A3 - Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg) - Google Patents

Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg) Download PDF

Info

Publication number
WO2023133260A3
WO2023133260A3 PCT/US2023/010301 US2023010301W WO2023133260A3 WO 2023133260 A3 WO2023133260 A3 WO 2023133260A3 US 2023010301 W US2023010301 W US 2023010301W WO 2023133260 A3 WO2023133260 A3 WO 2023133260A3
Authority
WO
WIPO (PCT)
Prior art keywords
smarca4
swi
subfamily
chromatin
matrix associated
Prior art date
Application number
PCT/US2023/010301
Other languages
English (en)
Other versions
WO2023133260A2 (fr
Inventor
Yu Liang
Eshini A. PANDITHARATNA
Jun Qi
Mariella FILBIN
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of WO2023133260A2 publication Critical patent/WO2023133260A2/fr
Publication of WO2023133260A3 publication Critical patent/WO2023133260A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

La présente divulgation concerne des composés bifonctionnels, des compositions et des méthodes de traitement de maladies ou d'affections médiées par une activité aberrante de SMARCA4 ou de SMARCA2 et de SMARCA4.
PCT/US2023/010301 2022-01-07 2023-01-06 Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg) WO2023133260A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263297505P 2022-01-07 2022-01-07
US63/297,505 2022-01-07

Publications (2)

Publication Number Publication Date
WO2023133260A2 WO2023133260A2 (fr) 2023-07-13
WO2023133260A3 true WO2023133260A3 (fr) 2023-08-17

Family

ID=87074155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/010301 WO2023133260A2 (fr) 2022-01-07 2023-01-06 Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg)

Country Status (1)

Country Link
WO (1) WO2023133260A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105518A1 (fr) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
WO2020010204A1 (fr) * 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Composés de dégradation/perturbation de la protéine tyrosine kinase 6 (ptk6) et méthodes d'utilisation
WO2020069105A1 (fr) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Agents de dégradation de la kinase wee1
WO2021236080A1 (fr) * 2020-05-20 2021-11-25 Foghorn Therapeutics Inc. Méthodes de traitement de cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105518A1 (fr) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
WO2020010204A1 (fr) * 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Composés de dégradation/perturbation de la protéine tyrosine kinase 6 (ptk6) et méthodes d'utilisation
WO2020069105A1 (fr) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Agents de dégradation de la kinase wee1
WO2021236080A1 (fr) * 2020-05-20 2021-11-25 Foghorn Therapeutics Inc. Méthodes de traitement de cancers

Also Published As

Publication number Publication date
WO2023133260A2 (fr) 2023-07-13

Similar Documents

Publication Publication Date Title
Reyes‐Dominguez et al. Heterochromatic marks are associated with the repression of secondary metabolism clusters in Aspergillus nidulans
Cherepanov LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro
MX9708663A (es) Inhibidor de actividad il-6.
ATE177420T1 (de) Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase
ATE244717T1 (de) Inhibitoren des impdh-enzyms
KR950702180A (ko) 류코트리엔 생합성 억제제로서의 치환된 아릴알키닐-및 헤테로아릴알키닐-N-하이드록시우레아(substituted arylalkynyl-and heteroarylalkyny-N-hydroxyurea inhibi tors of leukotriene biosynthesis)본 내용은 요부공개 건이므로 전문 내용을 수록하지 않았음
MX2022011534A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa.
WO2022031847A3 (fr) Compositions et méthodes d'inhibition de l'expression de plp1
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
WO2023133260A3 (fr) Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg)
WO2022218941A3 (fr) Compositions et procédés d'inhibition de la cétohexokinase (khk)
WO2021159008A3 (fr) Compositions et méthodes de traitement de maladies neurodégénératives
Clarke et al. RexAB is essential for the mutagenic repair of Staphylococcus aureus DNA damage caused by co-trimoxazole
AU2003238804A1 (en) Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
Kies et al. Identification of the sigB operon in Staphylococcus epidermidis: construction and characterization of a sigB deletion mutant
Koch et al. The chromatin remodeler Isw1 prevents CAG repeat expansions during transcription in Saccharomyces cerevisiae
WO2021222065A8 (fr) Compositions d'agent d'arni de l'apolipoprotéine e (apoe) et leurs procédés d'utilisation
Guirao-Abad et al. A human IRE1 inhibitor blocks the unfolded protein response in the pathogenic fungus Aspergillus fumigatus and suggests noncanonical functions within the pathway
CA3155921A1 (fr) Compositions d'agents a base d'arni ciblant la huntingtine (htt) et leurs procedes d'utilisation
AU2022349529A1 (en) Compositions for editing mecp2 transcripts and methods thereof
WO2019117662A3 (fr) Système crispr spécifique d'une mutation du promoteur de tert et son utilisation
AU2021315475A8 (en) Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
Paule et al. Faithful initiation of ribosomal RNA transcription from cloned DNA by purified RNA polymerase I
BR0016669A (pt) Composto, e, composição farmacêutica
Fagundes et al. Draft genome sequence of Staphylococcus agnetis 3682, the producing strain of the broad-spectrum lantibiotic agneticin 3682

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737621

Country of ref document: EP

Kind code of ref document: A2